Board of Directors

Board of Directors

  • Steve Aselage
    Chairman

    Mr. Aselage has more than 30 years of pharmaceutical and biotechnology experience, currently serving as Chief Executive Officer of Retrophin, Inc. (RTRX). Previously, he was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, he built the commercial and medical affairs functions that launched three commercial products […]

    VIEW MORE
  • Chris Schelling
    Chief Executive Officer & Founder, Director

    Mr. Schelling has 20 years of commercial strategy and orphan drug development expertise. Prior to founding Acer, he was Executive Director of Strategic Marketing at BioMarin Pharmaceutical (BMRN), where he was instrumental in the development and commercialization of the company’s phenylketonuria (PKU) franchise. Previously, he held roles at Abgenix, Cell Therapeutics, SRI Consulting, and Organon. […]

    VIEW MORE
  • Michelle Griffin
    Director

    Ms. Griffin currently provides consulting services to biotechnology companies and boards of directors through her firm, Pacific Biotechnology Consulting Group. Ms. Griffin served on the board of directors and chair of the audit committees for PhaseRx, Inc. from 2016 to 2018 (acquired by Roivant Sciences GmbH in 2018), OncoGenex Pharmaceuticals Inc. from 2008 to 2011 […]

    VIEW MORE
  • John M. Dunn
    Director

    Mr. Dunn has served as General Counsel to Vital Therapies, Inc., a public biotech company located in San Diego, California, since November 2014. Prior to joining Vital Therapies, Mr. Dunn was a consultant in the life science industry from February 2012 to November 2014. Mr. Dunn retired from Biogen in 2012 where he was an […]

    VIEW MORE
  • Jason Amello
    Director

    Mr. Amello is the Senior Vice President, Chief Financial Officer, and Treasurer of Akebia Therapeutics, Inc. and has held the position since 2013. Prior to joining Akebia, Mr. Amello served as Executive Vice President, Chief Financial Officer, and Treasurer of ZIOPHARM Oncology, Inc., from 2012 to 2013. From 2000 to 2011, Mr. Amello held various […]

    VIEW MORE
QUICK
NAV